The data concerning the use of non-steroidal anti-inflammatory drugs (NSAIDs) and evidence for their efficacy in laboratory rats and mice are reviewed. This information is then extrapolated to clinical situations and dose rates that take account of ulcerogenic side effects are recommended. NSAIDs have the potential to be a very useful group of analgesics and should always be considered when attempting to provide pain relief in laboratory animals.
Research workers have both an ethical and legal responsibility to provide pain relief to laboratory animals. There is a growing awareness within the veterinary and scientific communities of the need to provide adequate analgesia, but there is a lack of readily accessible data concerning the effects of the compounds which are available. In addition we currently are unable to assess clinical pain objectively and reliably in animals.
A wide range of different analgesic drugs are available for use in laboratory animals. These may be classified in a variety of ways, but it is convenient to consider them in 3 broad groups (Jenkins, 1987) : (i) The centrally acting agents, such as pethidine and buprenorphine that interact with endogenous opioid systems in the CNS.
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Received 1 November 1991; accepted 23 March 1992 (ii) Substances that block impulses from nociceptors such as the local anaesthetics, antihistamines and (X2 adrenoceptor agonists such as xylazine and medetomidine. (iii) Agents that inhibit the production of the chemical mediators that activate peripheral nociceptors, such as aspirin and paracetamol. The final group of analgesics are usually referred to as non-steroidal anti-inflammatory drugs (NSAIDs) . Although these are generally weaker analgesics than opioids (group i), this distinction is becoming less pronounced with the development of new, potent NSAIDs. Compounds such as paracetamol differ from 'conventional' NSAIDs since they have no anti-inflammatory properties but it is customary to include them in this group of analgesics. Opioids are the major group of analgesics in current clinical use in animals but they have a wide range of effects which are unrelated to their analgesic actions (Fog, 1970; Cowan et al., 1977; Bovill et al., 1984; Reid, 1985) and these side-effects may prevent their use in some situations. NSAIDs may therefore be useful alternatives for pain relief, particularly the more recently introduced compounds such as flunixin which may provide sufficient analgesia to alleviate acute postoperative pain (Reid & Nolan, 1991) . NSAIDs will relieve pain resulting from an inflammatory response to surgical trauma by suppressing the inflammation to some extent, but they also have varying degrees of specific analgesic actions (Taylor, 1985) . Abramson & Weissmann (1989) suggest that high doses of prostaglandin inhibiting NSAIDs are required for anti-inflammatory actions but lower doses produce anti-pyretic and analgesic effects. Pain due to inflammation at the site of a surgical wound may contribute significantly to the overall level of post-operative pain. Inflammation at an operative site develops several hours after the time of initial incision. It has been demonstrated in rats that the depression in locomotor activity following surgery is greatest 12-18 h following nephrectomy (Flecknell & Liles, 1991) and it is possible that this may be related to the development of inflammation at the surgical site. If some of the pain which occurs following surgery is related to inflammatory Liles & Flecknell changes, then NSAIDs may form a useful adjunct to the control of pain in these circumstances.
Experimental animals may also experience pain as a result of non-surgical procedures. For example, the use of adjuvants to augment antibody production, the injection of irritant chemicals or the production of neoplasia. Distress, rather than pain, may also occur as a result of febrile responses to certain experimental procedures. In some instances it may be practical to reduce or eliminate these responses using NSAIDs.
Clearly, there may be important constraints since the use of these compounds could frustrate the aim of a particular study. Nevertheless, in some instances, the inflammatory changes or febrile response may be an undesirable and unnecessary side-effect of the experiment.
Pharmacology of NSAlDs
There are two major functional classes of NSAIDs: the cyclo-oxygenase inhibitors and the aniline derived analgesics. The cyclo-oxygenase inhibitors can be subdivided into a number of groups based on their chemical structure, and Table 1 lists some of the more common members of each group. Differences in structure can result in differences in drug potency, but this is only advantageous when increased potency is accompanied by a reduction in the incidence and severity of side-effects.
Tissue injury caused by intense thermal, mechanical, or chemical stimuli results in the activation of phospholipase A2' an enzyme that catalyses the formation of arachidonic acid from cell membranes.
Arachidonic acid is a substrate for two enzymes: cyclo-oxygenase and lipoxygenase (Lees et al., 1991) . Cyclooxygenase generates two unstable endoperoxides, prostaglandin G2 and H2' which then form the stable prostaglandins E2' D2' F2' 12, prostacyclin and thromboxane.
Lipoxygenase forms monohydroperoxy fatty acids (HPETEs), monohydroxy acids (HETEs), eicosatetraenoic acids and the leukotriene family L TB4' L TC 4 , L TD4 and LTE4 (Forrest & Brooks, 1988) . There is considerable evidence to suggest that the arachidonic acid metabolites prostaglandins POE2 and POI 2 and the leukotriene LTB4 are, along with histamine, serotonin (5HT) and bradykinin, major mediators/modulators of inflammation (Lees et al., 1991) . Prostaglandins are believed to bind to receptors on the sensory nerve endings promoting the discharge of impulses and consequently causing an increase in pain. They also sensitize afferent nerve endings to the effects of a number of physical and chemical stimuli. Some prostaglandins also have effects that lead to inflammation, these include vasodilation, increased vascular permeability, oedema, and leucocyte migration.
The overall effect of prostaglandins and other mediators is to provide an amplification system for the peripheral pain mechanism by reducing the threshold of polymodal nociceptors and to initiate inflammatory reactions (Jenkins, 1987) .
Cyclo-oxygenase inhibiting NSAIDs cause a reduction in or stop the production of prostaglandins, prostacyclin and thromboxane. This leads to a smaller inflammatory response and therefore analgesia. The exact mechanism of action of the aniline-derived analgesics such as paracetamol is unclear but they too are believed to inhibit cyclo-oxygenase and reduce prostaglandin release centrally. However, this class of NSAIDs have few anti-inflammatory properties.
NSAIDs also have mechanisms of action that are not related to the arachidonic acid metabolites, these include inhibition of a variety of enzyme systems, some of which catalyse the formation of neurotransmitters which are involved in the central pain pathways. NSAIDs also produce changes in transmembrane ion fluxes (Abramson & Weissmann, 1989) . The enhanced membrane potentials and conductances which are produced after treatment with some NSAIDs decrease the probability of generating action potentials in nerves and so reduce the effectiveness of synaptic output (Rainsford, 1984) . Some NSAIDs, particularly the salicylates, exert central effects indirectly by 243 displacing tryptophan from albumin. Elevated levels of unbound tryptophan lead to increased synthesis of serotonin, a neurotransmitter which is thought to modulate pain in CNS pathways (Rainsford, 1984) . NSAIDs also inhibit a number of neutrophil functions, for example, most will inhibit neutrophil aggregation (Abramson et al., 1990) .
Assessment of analgesic efficacy Preliminary screening of potential analgesics for use in man is usually carried out in laboratory animals (Flecknell, 1984) . These tests measure the potency of different analgesics in preventing specific responses to defined nociceptive stimuli. They have been extensively reviewed elsewhere (Crepax & Silvestrini, 1963; Taber, 1974; Albengres et al., 1988) and only brief descriptions will be given here. A number of different noxious stimuli have been used, including thermal, electrical, chemical and mechanical stimuli. Another commonly employed test of NSAIDs is to induce polyarthritis by the injection of adjuvant and then assess the efficacy of analgesics in these animals.
Thermal stimulus
This usually involves placing the tail of a rat or mouse in a hot water bath (approximately 45°c_ 50°C) and recording the time it takes for the animal to remove or flick its tail. Analgesics are then given and the change in latency noted. This method of assessment is sometimes called 'the tail flick test'. Other thermal methods involve applying direct heat to shaved areas of skin and recording the time it takes for the skin to twitch.
Electrical stimulus
An electrical shock is given to the animal and then a defined response is noted. Analgesic treatment should increase the amplitude of the stimulus required to elicit the defined behaviour. Electrical shocks can be given to the whole animal, for example by placing it on a metal grid that the current passes through, or by directly stimulating a specific anatomical structure such as the tooth pulp.
Chemical methods
An injection of an irritant is given and a set response observed. The most common of these tests is the writhing test. In this, the chemical irritant is injected by the intraperitoneal route which usually causes the animals to writhe and stretch in a characteristic way. The number of specific movements or the time spent moving are then used as an index of pain. The response elicited depends upon the chemical irritant used and the dose. A large number of agents have been used in chemical tests, for example, acetylcholine, pheylbenzoquinone (PBQ) and acetic acid.
Mechanical forces
Varying magnitudes of mechanical forces can be applied to a digit or the tail and the animal's response, either physical or vocal, can be noted. Animals which have received analgesic will tolerate higher forces than control animals. A variant of these tests, developed to overcome the problem of insensitivity to NSAIDs, is called the 'inflamed paw pressure test'. In this test the animal's paw is made hypersensitive by the subplantar injection of an irritant such as trypsin or serotonin. After the irritant has elicited an inflammatory reaction a mechanical force is applied to the paw and the animal's response noted. The analgesic is then administered and the effect on the response latency noted.
Oedema tests
These are used to assess the anti-inflammatory, as opposed to the analgesic efficacy of different compounds.
Acute inflammation of a specific area, usually the paw of rodents, is induced by injecting an irritant such as carrageenin.
The size of the paw is then calculated by direct measurement or plethysmography.
Compounds with good anti-inflammatory efficacy cause smaller paw sizes than ones with little or no antiinflammatory actions.
Liles & Flecknell Analgesiometry and clinical pain Data obtained from experimental analgesiometry enable an assessment of the efficacy and relative potency of NSAIOs to be established. A selection of lethal doses (LD50) and effective doses (E0 50 ) of a range of NSAIDs are listed for mice and rats in Tables 2 and 3 . These data enable an initial assessment to be made of dose regimens that may be appropriate for clinical use of NSAIDs. Rabbits and guineapigs are seldom used in analgesiometric tests, therefore there are no data on effective doses in these species. Some authors have administered
NSAIDs to rabbits and guineapigs where the dose is extrapolated from other species. (For recommended doses based on these data for rabbits and guineapigs see Tables 6 & 7, respectively.)
Clinical pain is different from the pain produced in analgesiometric tests. Some of these tests only measure transient pain or pain thresholds, others like the chemically induced writhing test can simulate longer periods of pain but these are dependent upon the irritant used and the dose given (Vinegar et al., 1990) . There is no single test that exactly predicts clinical doses of NSAIDs in humans. Kistler (1988) points out that analgesiometric tests that use mechanical stimuli result in higher ED 50 values for all classes of analgesics and that tests that use chemical stimuli lead to smaller ED 5 0s and are therefore a more sensitive test. Taber (1974) and Crepax and Silvestrini (1963) both state that thermal, electrical and unsensitized mechanical tests are inadequate for the assessment of the efficacy of NSAIDs. Writhing tests and inflamed pressure tests are considered better tests of NSAIDs because the ED 5 0s obtained are nearer the doses that are used in human clinical cases.
In animals there is an additional problem when attempting to predict clinical doses from the results of analgesiometric tests. At present we are unable to objectively and accurately assess clinical pain in animals. If the level of clinical pain cannot be adequately assessed then it is not possible to determine if the treatment that has been given is adequate. There is, however, some evidence that doses of NSAIDs extrapolated 
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Fujiyoshi et al. (1990) from analgesiometric tests in rodents correlate well with clinical doses that are known to be effective in dogs. For example flunixin has been shown to be effective at altering post-operative pain in dogs (Reid & Nolan, 1991) . In this study pain was assessed using a visual analogue scale, and the analgesic effects of flunixin compared with papaveretum (an opioid analgesic). Clinical reports of the use of aspirin, paracetamol and other NSAIDs to control chronic and low grade pain in dogs (Yoxall, 1978; Taylor, 1985) support the contention that the dose rates used do provide effective analgesia. In larger species, similar clinical experience suggests that NSAIDs are effective analgesics. For example flunixin, naproxen and phenylbutazone in horses and flunixin and phenylbutazone in cattle and sheep are all recommended for clinical use (DeBuf, 1991) . There is a reasonable correlation between the results of rodent analgesiometry tests and the dose rates judged effective in those species in which clinical pain assessment methods have been best developed (dog and horse). This supports a similar extrapolation of the results of analgesiometry tests in rodents to establish clinical dose rates in these same species. Further support for the relevance of dose rates effective in analgesiometry tests is gained from data obtained in some chronic pain models which induce arthritis experimentally. Treatment of these animals with doses of NSAIDs based on analgesiometry test results led to increased movement and mobility (Colpaert, 1987) , indicating that the doses given are effective. Colpaert et al. (1980) showed that arthritic rats self administered the NSAID suprofen. This suggests that suprofen had a beneficial, and presumably analgesic effect because the rats chose to administer it. Until we can assess clinical pain in laboratory animals dose rates cannot be firmly established, but we can suggest doses based on analgesiometry, especially if we relate the type of test to the cause of the clinical pain. Writhing tests may therefore be more appropriate than one based upon oedema tests if the NSAID is being administered to treat peritonitis. However, a dose based upon oedema and inflamed paw pressure tests may be more appropriate if the NSAID is being given to reduce pain caused by post-operative inflammation.
Adverse effects of NSAIDs and selection of dose rates
The therapeutic index of the drugs mentioned in Tables 2 and 3 can be determined by comparing Otterness & Gans (1988) the EDso quoted with the LDso. Although this is an index of the safety of a compound, many NSAIDs have adverse effects at pre-lethal doses. The most common side-effect encountered with NSAIDs is gastric and intestinal ulceration. This is due both to local irritation and also because NSAIDs inhibit the production of POE, and POE2 in the gastric mucosa. These two prostaglandins usually regulate gastric secretions and promote the production of cytoprotective mucus in the digestive tract (Jenkins, 1987) . Table 4 presents the ulcerogenic doses (UD so ) of some of the NSAIDs and these too should be considered when determining a clinical regimen. It is also important to consider the possibility of drug interactions. For example flunixin has a potential nephrotoxic effect which has not proven to be of clinical significance, but when this drug was administered to dogs following methoxyflurane anaesthesia, renal toxicosis occurred (Mathews et al., 1990) . Methoxyflurane undergoes metabolism resulting in inorganic fluoride ion release, and produces a mild nephrotoxic effect. The combination of the two components was additive, and the possibility of similar interactions should always be considered when formulating treatment regimens. Table 5 lists some suggested doses for a few of the more common NSAIDs. These data are based upon consideration of the LDso, EDso and UD so as well as some clinical observations by the authors with flunixin. Although there are suggested doses for diclofenac and indomethacin, we do not recommend that these products are used because they have a very low therapeutic index. The bioavailability of most NSAIDs is high and they are readily absorbed when taken orally, although there are some exceptions. Diclofenac shows variable and low oral absorption so hence has a low bioavailability (Brune, 1988) . Flunixin, although available in tablet and granular forms, is more commonly administered as an injection, in fact it is one of the few NSAIDs that can be given parentally and this trait makes flunixin a valuable NSAID for use post-operatively, when oral administration may be impracticable. If paracetamol is to be administered to animals it is often useful to use the human paediatric preparations. These are low concentration palatable syrups that will readily be taken from a syringe by most animals
Use of NSAIDs in animals and man
In man NSAIDs have been used for many years to control pain in a variety of circumstances. In rheumatoid arthritis and osteoarthritis aspirin has been the drug of choice to control swelling and pain, although recently drugs such as diflunisal, with higher potencies and decreased gastric irritation, have replaced aspirin (Rainsford, 1984) . Paracetamol and other aniline derived analgesics are replacing the cyclo-oxygenase inhibitors' function of providing pain relief from headaches and migraines. NSAIDs have been used effectively alone or in combination with opioids to provide post-operative pain relief in man following surgery that causes large amounts of inflammation and bony or soft tissue damage (Smith & Covino, 1985) . NSAIDs alone can be used to control pain following some types of surgery, and following dental procedures. Alexander & Hill (1987) state that paracetamol alone can provide adequate analgesia following craniotomy. Rosenblum et al. (1991) report that patients treated with ibuprofen following laparoscopy were more comfortable and had longer lasting analgesia than those treated with fentanyl. Albengres et al. (1988) A range of other conditions including gout and cancer pain are also treated in man with NSAIDs. The antipyretic properties of NSAIDs are used to reduce febrile conditions and when treating rheumatic fever. Aspirin is used in a number of thromboembolic conditions because it irreversibly inhibits platelet aggregation.
In veterinary clinical practice the greatest use of NSAIDs is to treat inflammation and pain associated with musculo-skeletal disorders. The majority of NSAIDs that are marketed for veterinary use have product licences for the treatment of joint pain associated with various types of arthritis in large and small animals. In the horse a variety of NSAIDs, such as meclofenamic acid, phenylbutazone and f1unixin, are marketed for use in laminitis, tendinitis, navicular disease and following trauma or surgery when localized inflammation is likely to occur (DeBuf, 1991) . Flunixin (Finadyne, Schering-Plough, Mildenhall, Suffolk, UK) is recommended by the manufacturer for the treatment of musculo-skeletal pain, and also for the alleviation of post-operative pain in the Liles & Flecknell dog and the control of acute abdominal pain in equine colic. This compound has also been licensed for use in acute inflammatory conditions in cattle. Reid & Nolan (1991) compared post operative pain in dogs who received either f1unixin or papaveretum after a variety of surgical procedures and concluded that f1unixin was a good analgesic for the treatment of acute post surgical pain.
Combinations of paracetamol, butobarbitone and codeine (Budale-V, Arnolds, Reading, UK), and paracetamol, codeine and caffeine (Pardale-V, Arnolds) are marketed for analgesic therapy in the dog. These preparations are used for the control of traumatic pain, post-surgical pain and pain associated with musculo-skeletal disorders.
In addition to these compounds which have veterinary product licences for use in different species of animals, a number of authors have recommended the use of other NSAIDs for the control of both acute traumatic pain and chronic painful conditions such as neoplasia. Yoxall (1978) recommends that NSAIDs can be administered to dogs suffering from tumours in order to improve the 'quality of the dog's life'. Taylor (1985) suggests that NSAIDs can be used successfully in cats and dogs to treat pain arising from degenerative joint disease, tumours, periodontal disease, skin disease and other conditions where the problem is long lasting.
Suggestions for use in laboratory animals
At the moment NSAIDs are rarely used for alleviation of pain in laboratory animals. There is therefore virtually no clinical experience comparable to that which has been obtained in companion and farm animals (see above). At present, therefore, it is only possible to suggest situations where NSAIDs could be of potential benefit, based upon human medical and veterinary clinical experience. As our ability to assess pain in laboratory animals improves, both the suggested dose rates and potential applications of NSAIDs can be reviewed and reevaluated.
Currently, in many research laboratories, if pain is believed to be present following an experimental procedure opioid analgesics are administered. In some instances, opioids may be contraindicated because of the range of effects they exert on different body systems. If this is the case and there is a need to provide pain relief, then NSAIDs provide an alternative. Following minor procedures such as superficial skin incision or surgery that gives rise to inflammation of a localized area, NSAIDs may be sufficiently potent to provide complete pain relief. Following major surgery, which would normally require opioid therapy to alleviate post-operative pain, NSAIDs may be administered 24-72 h post-operatively once the initial acute pain has subsided. The authors have used this technique successfully in dogs, nonhuman primates and sheep. There is a considerable body of clinical opinion which suggests that flunixin can be used successfully to control moderate post-operative pain in pigs, sheep and cats in addition to dogs, horses and ponies. NSAIDs can also be used to treat inflammatory conditions which occur as an undesirable side-effect of experimental procedures, for example the authors have used aspirin and paracetamol to treat the mild proliferative gingivitis which occurred as a sideeffect of cyclosporin administration in dogs.
Once treated these dogs regained their appetites and no longer showed clinical signs of oral pain. Laboratory animals in which neoplasms have been produced as part of an experimental procedure may benefit from treatment with NSAIDs. Although in some instances such treatment could interfere with an experimental protocol, therapy might be permissible in other cases. A few immunized animals show excessive reactions upon injection of adjuvant and antigens. Clearly an inflammatory response is desirable in order to obtain a good immune response, but if an unpredicted severe reaction does occur, causing excessive distress, this could be controlled with a short period of treatment with NSAIDs. It is possible that a novel experimental protocol may lead to an animal experiencing endotoxic shock, if this is the case and it is not practicable to humanely kill the animal, then NSAIDs may be used to control this condition.
It is unrealistic to expect that NSAIDs can be administered to experimental animals in all circumstances. It is important, however, that a realistic and reasoned assessment is made of the need for therapy to control pain, inflammation or febrile responses and the possible contraindications to such treatment. Although NSAIDs do not provide such effective post-operative analgesia as opioids, they provide a useful alternative in situations where more potent compounds cannot be used because of scientific reasons. When using NSAIDs it is important to evaluate their efficacy in each clinical situation and adjust the dose given so that an appropriate treatment regimen can be established. 
